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Summary
Tumor angiogenesis is postulated to be regulated by the balance between pro- and anti-angiogenic factors. We demonstrate
that the critical step in establishing the angiogenic capability of human cells is the repression of the critical anti-angiogenic
factor, thrombospondin-1 (Tsp-1). This repression is essential for tumor formation by mammary epithelial cells and kidney
cells engineered to express SV40 early region proteins, hTERT, and H-RasV12. We have uncovered the signaling pathway
leading from Ras to Tsp-1 repression. Ras induces the sequential activation of PI3 kinase, Rho, and ROCK, leading to
activation of Myc through phosphorylation; phosphorylation of Myc via this mechanism enables it to repress Tsp-1 expres-
sion. We thus describe a novel mechanism by which the cooperative activity of the oncogenes, ras and myc, leads directly
to angiogenesis and tumor formation.
Introduction conduit through which tumors can metastasize to distant sites
(Cavallaro and Christofori, 2000; Folkman, 1985; Hanahan and
The process of tumorigenic transformation involves the sequen- Folkman, 1996). These observations underscore the importance
tial acquisition of a number of genetic and epigenetic alterations of elucidating the cancer cell-specific processes that enable
by the genomes of evolving, premalignant cell populations (Ha- tumors to interact with the existing vasculature and recruit neo-
nahan and Weinberg, 2000). These alterations culminate in a vasculature.
deregulation of the growth-controlling circuitry of cells. Among Observations of tumor growth have indicated that small
other biological changes, these alterations provide the tumor tumor masses of 1–2 mm diameter can persist in a tissue without
cell with constitutive mitogenic signals, deregulate the control any tumor-specific vasculature (Coussens et al., 1999; Hanahan
of the cell cycle, and, as shown in recent years, enable the et al., 1996; Holmgren et al., 1995). The growth arrest of nonvas-
maintenance of telomeric DNA (Artandi and DePinho, 2000; cularized tumors of this size has been attributed to the effects
Blasco, 2002; Bodnar et al., 1998; Kiyono et al., 1998).
of hypoxia at the center of the tumor since the diffusion of
In addition, the events that take place during tumor progres-
oxygen through living tissue is effectively limited to distancession enable the tumor to interact with its stromal environment
less than 200 m (Olive et al., 1992). It has been suggestedin ways that enhance its ability to proliferate in the primary site
that tumors emerge from this growth arrest by developing aand, in highly malignant tumors, to metastasize to distant sites
neovasculature, a change that has been termed the “angiogenicin the body (Brown et al., 1999; MacDougall and Matrisian,
switch” (Hanahan et al., 1996). However, direct proof for the1995). One of the key components of the tumor-associated
existence of this switch in spontaneously arising human tumorsstroma is the vasculature, which supplies oxygen, nutrients,
and an elucidation of its mechanism have remained elusive.and growth-promoting signals to the tumor cells and removes
Indeed, while the cell-to-cell signaling mechanisms that enablemetabolic waste generated by the tumor cells (Berse et al.,
1992). The newly acquired vasculature may also serve as a tumor cells to evoke angiogenesis have been intensively stud-
S I G N I F I C A N C E
Tumor dormancy is a critical yet poorly understood phenomenon affecting both the diagnosis and treatment of human cancers.
This is due in large part to the lack of model systems available to study dormant tumor cells. We have developed such cells via the
ectopic expression of the SV40 early region, hTERT, the catalytic subunit of telomerase, and H-RasV12. Modest overexpression of
H-RasV12 results in cells that form tumors unable to progress beyond approximately 2 mm in diameter. However, when VEGF is
overexpressed, or when thrombospondin-1 (Tsp-1) is repressed via antisense, the resultant cells form tumors that are unfettered in
their growth potential. This observation provides a mechanistic model for one form of tumor dormancy that is governed by the
regulation of the angiogenic potential of the tumor cells.
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ied, relatively little is known about the cell-autonomous pro- oncogenic Ras (3–7 above endogenous levels of wild-type
Ras expression, Figure 1C) form small tumors, approximatelycesses that enable tumor cells to induce angiogenesis.
1–2 mm in diameter, that never progress beyond this size. ThisSeveral growth factors act as positive regulators of angio-
behavior is in direct contrast to that of cells expressing highergenesis. Foremost among these are vascular endothelial growth
levels of Ras (12–50 above endogenous levels), which suc-factor (VEGF) (Leung et al., 1989), basic fibroblast growth factor
ceed in forming tumors of substantial size (1.5 cm diam.) within(bFGF) (Nguyen et al., 1994), and angiogenin (Hu et al., 1994;
3–7 weeks after implantation into host mice (Figure 1A). WeSoncin, 1992). Proteins such as thrombospondin (Tsp-1) (Good
speculated that the inability of the low Ras-expressing cells toet al., 1990), angiostatin (O’Reilly et al., 1996), and endostatin
grow beyond the diameter of 1–2 mm was attributable to a(O’Reilly et al., 1997) function as negative regulators of angio-
deficiency in angiogenesis.genesis.
To test this hypothesis directly, we ectopically expressedTsp-1 was the first naturally occurring inhibitor of angiogen-
VEGF in both the mammary and kidney cells. Indeed, overex-esis to be identified (Good et al., 1990). Tsp-1 inhibits the activity
pression of VEGF (400 pg/ml as measured by ELISA) resultedof MMP-9 (Rodriguez-Manzaneque et al., 2001), an extracellular
in the conversion of both low Ras-expressing cell types from amatrix (ECM) metalloproteinase that releases VEGF sequestered
nontumorigenic to a tumorigenic phenotype that rivaled the highin the ECM (Ribatti et al., 1998). In addition, Tsp-1 can act
Ras-expressing cells both in latency of tumor formation and indirectly to inhibit angiogenesis by binding to the CD36 receptor
growth kinetics (Figures 1A and 1B).protein, which is present on endothelial cell surfaces (Dawson
These observations suggested that high levels of Ras onco-et al., 1997).
protein cause significant levels of VEGF production, resultingBoth serum- and platelet-derived growth factor (PDGF)
in the robust tumorigenic growth of the high Ras-transformedtreatments upregulate the transcription of Tsp-1 (Framson and
cells; conversely, the low Ras-expressing cells, we imagined,Bornstein, 1993; Majack et al., 1987). The Ras oncoprotein, in
were unable to express and release significant levels of VEGF,direct contrast, inhibits the expression of Tsp-1 (Rak et al.,
explaining their weak tumorigenicity. Accordingly, we pro-2000). These conflicting responses suggest both positive and
ceeded to measure the amount of VEGF secreted by the cellsnegative effects of the mitogenic signaling pathway on Tsp-1
expressing no oncogenic Ras, low levels of oncogenic Ras, orexpression. In contrast to its effects on Tsp-1 expression, onco-
high levels of oncogenic Ras. We found that the level of VEGFgenic Ras stimulates VEGF expression (Rak et al., 1995), sug-
secreted by cells grown in 0.1% serum and 0.4% O2 was dra-gesting that Ras is an important regulator of the balance of pro-
matically higher in cells expressing low levels of Ras cells thanand anti-angiogenic factors.
in those carrying no ectopically expressed Ras oncoproteinThe creation of genetically defined human cancer cells has
(Figure 1C). However, the further increase in levels of VEGFprovided the opportunity to define with some precision the regu-
secretion observed when comparing the low Ras- to the highlatory pathways that contribute to the tumorigenic phenotype
Ras-expressing cells was a modest one of approximately 1.4-of human cancer cells (Hahn et al., 1999). In this laboratory, we
fold. These results suggested that the marginal differences inhave focused much attention on derivatives of three normal
VEGF expression levels by the low Ras versus high Ras cellshuman cell types (embryonic kidney cells, foreskin fibroblasts,
could not account for the marked disparity in the tumorigenicityand mammary epithelial cells) that have been transformed via
of these two cell populations.the retroviral transduction into these cells of the SV40 early
region, the catalytic subunit of human telomerase (hTERT), and
The balance of pro-and anti-angiogenic factorsthe oncogenic G12V allele of H-ras (Elenbaas et al., 2001; Hahn
regulates angiogenesis
et al., 1999). Following introduction of these genes, all three cell
These various observations, when taken together, suggested
types were tumorigenic and angiogenic when injected subcuta- that the differences in angiogenicity between the two cell popu-
neously into nude mice. lations might be traced to regulators of neovascularization other
In an effort to more closely recreate the signaling conditions than VEGF. Consequently, we turned our attention to the anti-
that operate in spontaneously arising human tumors, we created angiogenic factor, Tsp-1, and its expression. An immunoblot
versions of these human cancer cell lines that expressed lower analysis of proteins extracted from both the mammary and kid-
levels of H-RasV12 (Elenbaas et al., 2001) than those used in ney cells revealed that the level of Tsp-1 expression was essen-
the initial transformation experiments. In so doing, we discov- tially unchanged in the low Ras-expressing cells compared to
ered that the mammary epithelial and human embryonic kidney the cells not expressing oncogenic Ras (Figure 2A). However,
cells expressing the SV40 early region proteins, hTERT, and both cell types expressing high levels of oncogenic Ras exhib-
relatively low levels of H-RasV12 were either unable to form ited dramatically reduced levels of Tsp-1. In both the kidney cells
tumors when injected subcutaneously into nude mice or did so and mammary epithelial cells, the difference in Tsp-1 expression
only with long latency. As described herein, we have discovered between the low and high Ras-expressing cells was approxi-
that the prime defect of these cells is their inability to effectively mately 8-fold. This suggested that the poor angiogenicity of the
provoke neoangiogenesis. We therefore set out to determine low Ras-expressing cells was due to the high levels of Tsp-1
how signaling by the Ras oncoprotein enables cells to emerge that they produced.
from a non-angiogenic, poorly tumorigenic state. We speculated that an unfavorable ratio of VEGF to Tsp-1
might preclude neoangiogenesis in the tumors formed by the
Results low Ras-expressing cells. This model predicted that we could
confer a tumorigenic phenotype on the low Ras-expressing cells
Effect of Ras oncoprotein levels on Tsp-1 expression by decreasing the amount of Tsp-1 that they expressed. To
Human mammary epithelial- and kidney-derived cells that ex- examine this possibility, we created a retroviral vector specifying
antisense Tsp-1 and introduced this construct, via infection,press the SV40 early region, hTERT, and relatively low levels of
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Figure 1. Effects of VEGF on tumor formation
Growth curve of tumors formed by kidney-derived cells (A) and breast-derived cells (B) expressing low levels of Ras, low levels of Ras  VEGF, or high levels
of Ras.
C: ELISA of secreted VEGF by kidney and mammary derived cells expressing no (—), low, and high levels of oncogenic Ras grown in 0.1% O2.
into low Ras-expressing kidney cells. As hoped, the antisense ing only the periphery of the tumor (Figure 2F, panel iv). This
end-stage necrosis was characterized by a total absence ofconstruct reduced the levels of Tsp-1 protein expression in the
intact cells and the presence of fragmented nuclear and cyto-low Ras-expressing cells by roughly 4-fold (Figure 2B) (Castle
plasmic debris. Consistent with an impairment in angiogenesis,et al., 1991). These cells formed subcutaneous tumors in nude
this rim of viable cells was no more than 200 m in thicknessmice with a latency and kinetics that were comparable to those
at any given point (Figure 2F, panel ii). On the other hand, theof the high Ras-expressing cells, reaching the diameter of 1.5
tumors formed by the cells expressing high Ras and vectorcm within 7 days of one another (i.e., 34 versus 41 days) (Figure
alone formed solid masses that had only sparse patches of2C). As anticipated, the parental low Ras cells expressing only
necrosis comprising 5%–10% of the tumor (Figure 2F, panel i).the resistance marker (zeocin) were unable to form tumors dur-
When tumor size and viability are taken into account, the viableing this period (Figure 2C).
tumor burden of the mice bearing tumors of high Ras-expressingTo further confirm the role of Tsp-1 in tumor formation and
cells was more than 8-fold greater than that of the mice bearingangiogenesis, we transduced the high Ras-expressing kidney
tumors formed by Tsp-1-expressing cells. These observations
cells with a construct specifying Tsp-1. The resultant cells ex-
confirmed that the ratio between secreted VEGF and Tsp-1
pressed Tsp-1 levels similar to the parental cells expressing no strongly influences the angiogenicity of these tumor cells, and
oncogenic Ras (Figure 2D). When the two cell types were in- that angiogenicity and tumorigenicity can be achieved either by
jected into nude mice, the cells expressing Tsp-1 formed tumors increasing the expression of VEGF or by reducing the expression
approximately 60% smaller than those expressing vector alone of Tsp-1.
(Figure 2E). Furthermore, microscopic examination revealed that
the center of the tumors formed by the cells ectopically express- The role of Myc in Tsp-1 regulation
ing Tsp-1 were completely necrotic (comprising 60%–90% of Ras signaling has been demonstrated to affect the stability of
the Myc protein (Sears, et al., 2000). Furthermore, previoustotal tumor volume) (Figure 2F, panel ii) with viable cells compris-
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Figure 2. Tsp-1 expression and tumor formation
A: Immunoblot analysis of Tsp-1, -actin, and Ras proteins expressed in kidney- and breast-derived derived cells.
B: Immunoblot analysis of Tsp-1, -actin, and Ras expressed by kidney-derived cells expressing no (—), low, or high levels of Ras or of cells expressing low
Ras plus antisense Tsp-1 (AT).
C: Growth curves of tumors formed by kidney-derived cells expressing no (—), low, or high levels of Ras and cells expressing low Ras plus antisense Tsp-1 (AT).
D: Immunoblot analysis of Tsp-1, -actin, and Ras expressed by kidney-derived cells expressing no (—), low, or high levels of Ras or of cells expressing high
Ras plus Tsp-1.
E: Growth curves of tumors formed by kidney-derived cells expressing no (—), low, or high levels of Ras and cells expressing high Ras plus Tsp-1.
F: HE staining of tumors formed by cells expressing high levels of Ras plus control vector (i and iii) and high levels of Ras plus Tsp-1 (ii and iv). Upper panels
are 4 magnification and lower panels are 40 magnification. M denotes normal mouse tissue, V denotes areas of viable tumor cells, N denotes areas
of necrosis.
work has suggested a role for Myc in the repression of Tsp-1 (Littlewood et al., 1995). In the absences of tamoxifen, this
protein is functionally inactive and sequestered in the cyto-expression (Ngo et al., 2000; Tikhonenko et al., 1996). Conse-
quently, we examined whether the Ras-induced repression of plasm. Following 4-HT addition, it is rapidly activated and mi-
grates to the nucleus. This hybrid protein therefore makes itTsp-1 also depended on the activation of Myc. To this end,
we introduced an inducible dominant-negative version of Myc possible to induce DN Myc activity through the addition of 4-HT
to the growth medium.(DNMycER) into the high Ras-expressing kidney cells. This ver-
sion of Myc lacks the box 2 region (amino acid residues 106–143) In high Ras-expressing kidney cells that expressed
DNMycER, treatment with 4-HT induced the level of Tsp-1 toand is able to bind its cofactors, but is unable to form a functional
transcription complex (MacGregor et al., 1996). In addition, this rise within 4 hr, eventually reaching that of the cells expressing
no oncogenic Ras by 8 hr after 4-HT addition. In contrast, mock-version of Myc has been fused to a modified version of the
estrogen receptor that is activated only by tamoxifen (4-HT) treated and control cells were unchanged in their expression of
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to the culture medium (Littlewood et al., 1995). Upon treatment
with 4-HT, these low Ras cells exhibited reduced expression of
Tsp-1 protein within 4 hr. By 8 hr after 4-HT addition, the levels
of Tsp-1 expression in these low Ras kidney cells decreased
to the level of Tsp-1 expression seen in the high Ras kidney
cells; mock-treated cells were unchanged in their expression
of Tsp-1 (Figure 3B). Expression of both the wtMycER and
DNMycER proteins was confirmed by Western blot analysis
(Figure 3E). Furthermore, low Ras-expressing kidney cells trans-
fected with a construct specifying wt Myc also exhibited re-
duced expression of Tsp-1 protein at a level comparable to that
seen in the high Ras-expressing kidney cells (Figure 3C).
The fact that overexpression of wt Myc in low Ras-express-
ing cells is able to repress Tsp-1 expression to levels compara-
ble to the high Ras-expressing cells indicates that the Ras sig-
naling pathway is functional in these cells. However, the inability
of these cells to activate the endogenous Myc protein suggests
that either the level of Ras signaling is insufficient to activate
the endogenous Myc protein, or that the level of Myc protein
in these cells is insufficient. We concluded from these results
that Myc activity is required for the repression of Tsp-1 by Ras,
and that interference with endogenous Myc activity is sufficient
to abolish this repression.
Having established a role for Myc in the Ras-induced repres-
sion of Tsp-1, we proceeded to examine the effect of Ras signal-
ing on the levels of Myc protein expression in the mammary
cells and kidney cells, doing so at 0.1% serum in order minimize
the effects of mitogenic signals from sources other than onco-
genic Ras. We observed that Myc protein levels were unaffected
by the expression levels of the Ras oncoprotein (Figure 3D).
This ruled out the possibility that high levels of Ras were inducing
the accumulation of increased levels of Myc, thereby mimicking
the overexpression of Myc observed in several types of human
tumors (Little et al., 1983; Seshadri et al., 1989; Trent et al.,
1986). Hence, if high levels of Ras were acting through Myc to
Figure 3. Effects of Myc activity on Tsp-1 expression repress Tsp-1, we reasoned that this action must depend on a
A: Immunoblot analysis of Tsp-1, -actin, and Ras proteins expressed by mechanism distinct from any effects on the levels of the Myc
kidney-derived cells expressing no oncogenic Ras (—) or high levels of protein.
oncogenic Ras, or high levels of oncogenic Ras plus dominant-negative
MycER (DER), at 2, 4, 6, and 8 hr after treatment with 4-HT.
Effect of Ras signaling on Myc phosphorylationB: Immunoblot analysis of Tsp-1, -actin, and Ras proteins expressed by
kidney-derived cells expressing no oncogenic Ras (—) or low levels of onco- and activity
genic Ras plus MycER (MER) at 2, 4, 6, and 8 hr after treatment with 4-HT. We reasoned that if high levels of Ras were not inducing in-
C: Immunoblot analysis of Tsp-1, -actin, and Ras proteins expressed by creased levels of Myc, perhaps Ras might be affecting the phos-
kidney-derived cells expressing no oncogenic Ras (—), low levels of onco-
phorylation state of Myc. To pursue this possibility, we examinedgenic Ras, high levels of oncogenic Ras, or low levels of oncogenic Ras
the phosphorylation state of the Myc protein in these variousplus a transfected wt myc oncogene (M).
D: Immunoblot analysis of total Myc and -actin proteins expressed by cell populations. When cells were grown in 0.1% serum, we
kidney- and breast-derived cells expressing no oncogenic Ras (—), low observed a modest increase in the level of phosphorylated Myc
levels of oncogenic Ras, or high levels of oncogenic Ras.
in low Ras cells compared to those not expressing oncogenicE: Immunoblot analysis of wtMycER or DNMycER, -actin, and Ras proteins
Ras (Figure 4A). However, the amount of phosphorylated Mycexpressed by kidney-derived cells expressing low levels of oncogenic Ras
plus MycER (wt) or high levels of oncogenic Ras plus dominant-negative was dramatically increased in the cells expressing high levels
MycER (DN). of oncogenic Ras when compared to the level seen in low Ras
cells. The level of phosphorylated Myc was determined by im-
munoblot analysis with an antibody that recognized Myc protein
either singly phosphorylated at T58 or doubly phosphorylated
Tsp-1 protein (Figure 3A). This provided evidence that the Myc at residues T58 and S62 (Figure 4A). These results demonstrate
protein of the high Ras-expressing cells was participating in the that Myc phosphorylation modulated by Ras correlates with the
repression of Tsp-1 expression. repression of Tsp-1 expression.
We then attempted the opposite experiment by introducing Phosphorylation of Myc at residues T58 and S62 alters its
a vector expressing MycER into the low ras-expressing kidney ability to transactivate gene expression (Gupta et al., 1993; Seth
cells. This MycER construct specifies a wild-type Myc protein; et al., 1991) in addition to its effects on metabolic stability (Sears
et al., 2000). Furthermore, mutation of S62 to alanine inhibitsas before, this fusion protein is activatable by addition of 4-HT
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sion, MycS62A should act in a dominant-negative fashion by
titrating out Myc partner proteins such as Max (Blackwood and
Eisenman, 1991). To test this directly, we utilized the trans-
formed human kidney cells, which, in contrast to the mammary
cells, can be readily transfected. Indeed, as expected, transient
transfection of high Ras-expressing cells with MycS62A resulted
in the loss of Tsp-1 repression (Figure 4B). Furthermore, by
immunoblot analysis with anti-phosphoMyc antibody, we deter-
mined that phosphorylation at residue 58 was also abolished
by the S62A mutant (Figure 4B). This could be attributed to the
degradation of Myc protein phosphorylated only at T58, or to
phosphorylation at residue 62 being a prerequisite for phosphor-
ylation at residue 58 (Lutterbach and Hann, 1994).
While no role for phosphorylation at residue S71 has pre-
viously been identified, we found, in fact, that transient expres-
sion of a mutant Myc carrying a single amino acid substitution
at residue 71 (i.e., S71A) also acted in dominant-negative fashion
to relieve repression of Tsp-1 (Figures 4B and 4C). All the while,
transient transfection of low Ras-expressing kidney cells with
MycS62A and MycS71A had no effect on the level of Tsp-1
protein (Figure 4C). In addition, expression of MycS71A had no
effect on the phosphorylation of Myc at T58 and S62 in the
high Ras-expressing cells (Figure 4C). This result suggests that
phosphorylation of Myc at S71 is the ultimate activating event
responsible for the repression of Tsp-1.
The effects of the phosphorylation-defective mutants were
then assayed on an established target of Myc—the gene en-
coding ornithine decarboxylase (ODC)—using a ribonuclease
protection assay (RPA). Transient transfection of the low Ras-
expressing kidney cells with wild-type Myc resulted in the upreg-
ulation of ODC mRNA, while S62A and S71A had no effect
(Figure 4D). At the same time, transient transfection of the high
Ras-expressing kidney cells with either S62AMyc or S71AMyc
resulted in the downregulation of ODC mRNA (Figure 4D). These
results confirmed that phosphorylation at S62 and S71 is re-
quired for Myc function both as a transactivator and as a re-
pressor.Figure 4. Effects of Myc phosphorylation on Tsp-1 expression
A: Immunoblot analysis of phospho Myc and -actin proteins expressed by
kidney- and breast-derived cells expressing no oncogenic Ras (—), low Mechanism of repression of Tsp-1 expression by Ras
levels of oncogenic Ras, or high levels of oncogenic Ras. The above experiments indicated that signaling downstream
B: Immunoblot analysis of Tsp-1, phospho Myc, -actin, and Ras proteins
from Ras was regulating the repression of Tsp-1, and that thisexpressed by kidney-derived cells expressing high levels of oncogenic Ras
repression was dependent upon the activity of Myc. We there-transfected with S62AMyc (62) or S71AMyc (71) genes.
C: Immunoblot analysis of Tsp-1, -actin, and Ras proteins expressed by fore decided to further characterize the functional interactions
kidney-derived cells expressing low levels of oncogenic Ras, or high levels between these two proteins and the Tsp-1 gene. To begin, we
of oncogenic Ras that were mock transfected or transfected with S62AMyc
sought to determine which of the effector pathways downstream(62) and S71AMyc (71) genes.
D: Ribonuclease protection assay of ornithine decarboxylase (ODC) and of Ras was responsible for suppressing Tsp-1 expression. At
cyclophilin expressed in kidney-derived cells expressing no oncogenic Ras least three signaling pathways have been shown to be controlled
(—), low levels of oncogenic Ras, or high levels of oncogenic Ras that by the Ras protein (White et al., 1995), and several others maywere mock transfected or transfected with wtMyc (Myc), S62AMyc (62), or
also be perturbed in still poorly understood ways. The threeS71AMyc (71) genes.
major Ras effector pathways enumerated to date involve the
Raf-MAPK cascade, the phosphatidyl inositol-3 kinase (PI3K)
enzyme, and the Ral guanine nucleotide dissociation stimulator
(RalGDS) protein.soft agar colony formation conferred by this protein (Pulverer
et al., 1994). In order to assess the role of Myc phosphorylation In order to dissect the contributions of these three Ras
effector pathways to Myc-mediated Tsp-1 repression, we usedmore directly, we utilized phosphorylation-defective mutants of
Myc containing alanine substitutions at two of the sites that chemical inhibitors of the Raf and PI3K pathways. Treatment
of the high Ras-expressing kidney cells with U0126, a specifichave been shown to be phosphorylated, specifically, S62A and
S71A (Noguchi et al., 1999). We anticipated that if phosphoryla- inhibitor of MEK1/2 (Favata et al., 1998) that blocks ERK1/2
phosphorylation in the Raf-MAPK pathway, had no effect ontion at residue 62 were required for Myc-mediated Tsp-1 repres-
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Tsp-1 expression in cells ectopically expressing effector loop
mutants of Ras that signal primarily through only one of the
three major downstream effector pathways (White et al., 1995).
Only the PI3-kinase effector loop mutant (C40), which retains
PI3K-activating ability but lacks the other two effector functions
of Ras, was able to downregulate Tsp-1 expression. In contrast,
the Ras mutant that retains the ability to activate the RalGDS
(G37) pathway had no effect on Tsp-1 levels, and selective
activation of the Raf pathway by the third mutant (S35) actually
increased Tsp-1 expression (Figure 5C). Taken together, these
results indicated that the ability of Ras to downregulate Tsp-1
expression is attributable largely, if not entirely, to its ability to
activate PI3K.
PI3 kinase repression of Tsp-1
We next sought to determine the downstream effectors of PI3K
involved in the repression of Tsp-1. The best-studied effect of
PI3K involves its actions on the Akt/PKB kinase (Franke et al.,
1995). Accordingly, we attempted to mimic the actions of PI3K
by expressing a constitutively active mutant of Akt that contains
a myristoylation sequence at its carboxyl terminus (Ramaswamy
et al., 1999). Cells not expressing oncogenic Ras but expressing
the constitutively active version of Akt failed to downregulate
Tsp-1 protein levels (Figure 6A). An essential role of Akt/PKB
in Tsp-1 repression could be further excluded by retroviral trans-
duction of a dominant-negative mutant of Akt (Hoover et al.,
2001) into the high Ras-expressing kidney cells. This mutant
had no effect on the expression of Tsp-1, whereas it was able
to block the phosphorylation of Bad, a downstream target of
Akt (data not shown). Hence, Akt signaling was neither neces-
sary nor sufficient for the repression of Tsp-1.
Having excluded a role for Akt in Tsp-1 repression, we turned
our attention to other molecules activated by PIP3, the product
of the PI3K enzyme. Several guanine exchange factors (GEFs)
for the Rho family of GTPases have been identified that contain
Figure 5. Effects of Ras signaling pathways on Myc phosphorylation and PH domains which bind to PIP3 (Holsinger et al., 1995). To
Tsp-1 expression determine whether Rho proteins were likely to be involved in
A: Immunoblot analysis of Tsp-1, phospho Myc, phospho ERK1/2, -actin, mediating the PI3K effects on Myc and Tsp-1, we performed
and Ras proteins expressed by kidney-derived cells expressing no onco- GST-Rhotekin pulldown assays to assess the levels of GTP-
genic Ras (—), low levels of oncogenic Ras, or high levels of oncogenic
bound Rho in the no Ras-, low Ras-, and high Ras-expressingRas that were otherwise untreated or treated with either UO126 or LY294002.
cells (Ren and Schwartz, 2000). Indeed, Rho-GTP levels wereB: Immunoblot analysis of Tsp-1, phospho Myc, -actin, and Ras proteins
expressed by breast-derived cells expressing no oncogenic Ras (—), low approximately 10-fold greater in the high Ras-expressing cells
levels of oncogenic Ras, or high levels of oncogenic Ras that were otherwise than in the low Ras-expressing cells, while total Rho protein
untreated or treated with either UO126 or LY294002.
levels were constant (Figure 6B). Furthermore, treatment ofC: Immunoblot analysis of Tsp-1, -actin, and Ras proteins expressed by
the high Ras cells with LY294002 reduced the level of GTPkidney-derived cells expressing no oncogenic Ras (—), high levels of onco-
genic Ras, RasV12C40 (C40), RasV12G37 (G37), and RasV12S35 (S35). bound Rho to that of the no Ras- and low Ras-expressing cells
(Figure 6B).
These observations indicated a correlation between the lev-
els of Myc phosphorylation, Tsp-1 repression, and Rho activa-
the level of Tsp-1 protein (Figure 5A). In contrast, treatment of tion. This suggested the possibility that PI3K was acting through
the high Ras-expressing cells with the PI3K inhibitor LY294002 Rho proteins to achieve Myc phosphorylation and Tsp-1 repres-
(Vlahos et al., 1994) completely abrogated Tsp-1 repression sion. To assess the possible role of Rho as an intermediate
and restored Tsp-1 protein levels to those seen in cells not in this signaling cascade, we introduced a dominant-negative
expressing oncogenic Ras (Figure 5A). Consistently, Myc phos- mutant allele of the RhoA gene (RhoAN19) (Olson et al., 1995)
phorylation was strongly inhibited in both high Ras-expressing into the high Ras-expressing kidney cells. Ectopic expression
cells treated with LY294002, while treatment with U0126 had of RhoAN19 relieved the repression of Tsp-1 in high Ras-
no effect on Myc phosphorylation (Figure 5B). These results expressing cells, restoring the level to that seen in the low Ras-
allowed the tentative conclusion that it is the PI3K effector path- expressing cells (Figure 6C). We further explored the possible
way that plays a dominant role in the Ras-mediated phosphory- involvement of Rho by ectopically expressing mutant, constitu-
lation of Myc and repression of Tsp-1. tively active versions of RhoA and RhoC in the low Ras cells.
Indeed, when these cells were infected with a retroviral vectorThese results were confirmed and extended by analyzing
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Figure 6. Effects of Rho signaling on Myc phosphorylation and Tsp-1 expression
A: Immunoblot analysis of Tsp-1 and -actin proteins expressed by kidney-derived cells expressing no oncogenic Ras (—), low levels of oncogenic Ras, or
high levels of oncogenic Ras, or no oncogenic Ras plus myristoylated Akt (mAkt).
B: Immunoblot analysis of GTP bound Rho and total Rho in kidney-derived cells expressing no oncogenic Ras (—), low levels of oncogenic Ras, high levels
of oncogenic Ras, or high levels of oncogenic Ras plus LY294002.
C: Immunoblot analysis of Tsp-1, -actin, and Ras proteins expressed by kidney-derived cells expressing low levels of oncogenic Ras, low levels of oncogenic
Ras plus RhoCV14 (CV14), high levels of oncogenic Ras, high levels of oncogenic Ras plus RhoAN19 (AN19), and high Ras plus dominant-negative Akt
(DNAkt).
D: Immunoblot analysis of Tsp-1, phospho Myc, -actin, and Ras proteins expressed by kidney-derived cells expressing low levels of oncogenic Ras, low
levels of oncogenic Ras plus RhoAV14 (AV14), high levels of oncogenic Ras, or high levels of oncogenic Ras plus Y27632.
E: Immunoblot analysis of Tsp-1 and -actin expressed in human breast cancer cell lines treated with Y27632, LY294002, or mock treatment (—).
expressing RhoCV14 or transfected transiently with a vector Tsp-1 expression, restoring the level to that of low Ras-express-
ing cells, and at the same time abolished the phosphorylationexpressing RhoAV14, Tsp-1 expression was suppressed (Fig-
ures 6B and 6C). Taken together, these observations provided of Myc (Figure 6C). Together, these lines of evidence indicated
that Rho signaling is necessary and sufficient for Tsp-1 repres-strong indication that Rho serves as a conduit through which
the Ras protein signals to induce the repression of Tsp-1 expres- sion, and that this repression was achieved through the actions
of the Rho-associated kinase, ROCK. The involvement of ROCKsion.
in the regulation of angiogenesis represents a novel activity, asWe next sought to determine the downstream effector of
the only effects of ROCK activation reported to date have beenRho involved in the repression of Tsp-1. Two of the major ef-
related to cytoskeletal rearrangement and motility (Amano etfectors of Rho are p160ROCKI and ROCKII (two Rho-associated
al., 1996; Kawano et al., 1999).coiled-coil containing protein kinases) (Leung et al., 1996; Mat-
sui et al., 1996). Inhibition of ROCK with the specific inhibitor
Y27632 (Uehata et al., 1997) inhibits Ras-induced focus forma- Repression of Tsp-1 in human breast cancer cell lines
We then sought to determine whether the PI3K/Rho pathwaytion and transformation (Sahai et al., 1999). Treatment of high
Ras-expressing cells with Y27632 relieved the repression of was active in establishing the angiogenic program in human
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tumor cell lines. To this end, we made use of the human breast
cancer cell lines MDA-MB-231, MDA-MB-435, BT549, MCF7,
and SkBr3. We found that Tsp-1 expression was undetectable
in all of the above cell lines. Furthermore, when MDA-MB-231,
MDA-MB-435, and SkBr3 were treated with the PI3 kinase inhib-
itor, LY294002, or the ROCK inhibitor, Y27632, Tsp-1 levels
dramatically increased after 8 hr of treatment (Figure 6E). This
result further confirms that this pathway is active in several
human breast cancer cell lines and plays a role in establishing
the angiogenicity of human tumors.
Discussion
In previous work, we demonstrated the genetic requirements
for the formation of experimentally transformed human cells
(Elenbaas et al., 2001; Hahn et al., 1999). This work shed no
light, however, on the mechanisms whereby these cells acquired
an essential attribute of tumorigenicity, specifically angiogeni-
city. In the course of the present work, we have uncovered a
novel signaling pathway that leads from the Ras oncoprotein
via Myc to the repression of expression of the potent anti-
angiogenic protein, Tsp-1. The present results suggest that in
human cells, repression of Tsp-1 expression is a critical step
in the acquisition of angiogenicity and tumorigenicity. One
method of achieving Tsp-1 repression is via a PI3K-mediated
activation of Myc.
Once sufficient levels of PI3K activity are achieved, they
act, as demonstrated here, via a hitherto unidentified signal
transduction cascade, which leads through a Rho GEF to Rho
and ROCK to the activation of Myc. The identity of the kinase
or kinases directly responsible for the phosphorylation and func- Figure 7. Schematic diagram of signaling pathway from Ras to Tsp-1
tional activation of Myc at residues 62, and 71 is not addressed
by the present work. This may be achieved directly by ROCK,
or alternatively, ROCK may act via a cascade of intermediary
regression. This blood vessel regression could not be rescuedkinases to modify the Myc protein (Figure 7). In addition, we have
by the ectopic expression of VEGF, suggesting that Ras wasdiscovered that this pathway is also involved in the repression of
doing more than merely inducing VEGF expression. These ob-Tsp-1 in several human breast cancer cell lines.
servations are compatible with the presently demonstrated roleIt has been known for some time that a myc oncogene can
of Ras in repressing expression of Tsp-1, a protein known tocooperate with a ras oncogene to transform rodent cells (Land
be able to cause apoptosis of endothelial cells (Guo et al., 1997).et al., 1983). We have demonstrated here that a form of myc 
More recently, a murine transgenic model of pancreatic can-ras cooperation in human cells is also required for steps subse-
cer revealed that Myc expression was required for both thequent to the initial transformation event, namely the acquisition
establishment and maintenance of the tumor vasculature (Pel-of the angiogenic phenotype. The results presented here also
engaris et al., 2002). This model made use of the tamoxifen-provide insight into a novel regulation of Myc, a protein that
inducible MycER fusion protein and, similar to the observationshas been implicated in a number of forms of human cancer
made with inducible Ras, withdrawal of tamoxifen and subse-(Escot et al., 1986; Little et al., 1983; Trent et al., 1986). The
quent inactivation of Myc resulted in blood vessel regression.ability of Myc to function as an oncoprotein inducing anchorage-
The results of these two studies in a rodent experimental systemindependent growth has been found to be connected to its
strongly suggest that both Ras and Myc play dominant rolesstate of phosphorylation (Henriksson et al., 1993; Pulverer et
in triggering angiogenesis. Our findings provide a mechanismal., 1994). We demonstrate here that activation of Myc via phos-
phorylation is sufficient to confer an angiogenic phenotype by explaining these observations and extend them to human cells.
While previous work has shown that supra-physiologic lev-repressing the expression of Tsp-1, even in the absence of Myc
overexpression. Indeed, levels of Myc expression are unaltered els of oncogenic Ras are capable of downregulating Tsp-1 ex-
pression (Rak et al., 2000), and that ectopic expression of PTENby signaling from the Ras oncoprotein. Moreover, this observa-
tion suggests that the various contributions of the myc gene to can lead to an increase in Tsp-1 expression (Wen et al., 2001),
the signaling pathway(s) that regulate this repression have re-tumorigenesis have not been fully enumerated.
In a murine model of melanoma that utilizes a doxycyclin- mained uncharacterized. The present results indicate that onco-
genic Ras, expressed at near-physiologic levels, is not sufficientinducible transgene specifying H-RasV12, Ras signaling is re-
quired for the maintenance of the tumor vasculature (Chin et to repress Tsp-1. Our observations indicate that there are at
least two processes that are required in order for tumors toal., 1999). Interestingly, in this model, withdrawal of doxycyclin
and subsequent loss of Ras expression led to blood vessel downregulate the expression of thrombospondin-1. They are
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amplification or overexpression of myc, as is seen in many dation of the signaling pathways that regulate the expression
of VEGF, one of the most potent angiogenic factors. However,human tumors (Escot et al., 1986; Little et al., 1983; Nau et al.,
1984), and hyperactivation of the PI3K/Rho pathway. The latter to date, relatively little has been learned of the mechanisms
governing the expression of Tsp-1. The results presented hereevent may be achieved by point mutation in the ras oncogene,
mutation or overexpression of a growth factor receptor such as support the hypothesis that neoangiogenesis and thus tumor
progression are governed by the relative levels of pro- and anti-Her2/neu, or loss of the PTEN tumor suppressor protein. This
hypothesis is supported by our observation that overexpression angiogenic factors, specifically VEGF and Tsp-1 (Hanahan and
Folkman, 1996). Significantly, the ability of Ras to promote angi-of wt Myc in low Ras-expressing cells is necessary and sufficient
to repress Tsp-1 expression. ogenesis and hence tumorigenicity is governed in the presently
studied cells far more by its ability to repress Tsp-1 expressionFurthermore, we have identified three breast cancer cell
lines that repress Tsp-1 via the PI3K/Rho pathway. These cell than its effects in upregulating VEGF expression. These findings
raise the hope that chemical inhibitors that disrupt the path-lines activate the PI3K/Rho pathway via distinct mechanisms,
either through mutation in K-Ras (MDA-MB-231), overexpres- way(s) leading to Tsp-1 repression may prove to be effective in
diminishing the angiogenicity of certain human tumors and, insion of HER2 (SkBr3), or alteration of the PI3 kinase pathway
(MDA-MB-435) (Kozma et al., 1987; Singhal et al., 1994). At the turn, slow or even halt their further progression.
same time, MCF7 cells, which have amplified the myc locus,
Experimental proceduresand in which only minimal signaling, from Ras or PI3 kinase,
may be required to repress Tsp-1, were insensitive to chemical
Cell lines and constructs
inhibitors that affect this pathway. This opens the possibility The retroviral constructs expressing mVEGF were created by digesting the
that there is at least one other mechanism for repressing Tsp-1 vector pmVEGF164 (a gift from Bruce Spiegelman, Dana Farber Cancer
expression. For example, expression of Tsp-1 has been shown Institute) with BamH1 and EcoR1, and ligating it to similarly digested pBabe-
Zeo or pWZLBlast to create pBabeZeo-VEGF and pWZLBlast-VEGF. Theto be silenced by methylation in both colorectal cancer cell lines
retroviral vector pWZLBlast-Tsp1 was created by digesting the vectorand hematopoietic malignancies (Li et al., 1999). Additionally,
pCDNATsp-1 (a gift from Michael Detmar, Harvard Medical School) withit has recently been shown that Id1 is required for the repression
EcoRI and SalI and ligating the tsp-1 DNA to similarly digested pWZLBlast.
of Tsp-1 in both murine embryonic fibroblasts and endothelial The retroviral vector pWZLBlast-DNmycER was created by digesting pBabe-
cells (Volpert et al., 2002). Therefore, it is possible that Tsp-1 Puro-DNMycER (a generous gift from Gerard Evan, UCSF) with EcoRI, and
expression is regulated differently in various cell types or during ligating the DNA to pWZLBlast and orientation confirmed by restriction digest
with BamHI. The retroviral vector pBabeZeo-AT was created by digestingdistinct stages of development.
pWZLBlast-Tsp1 with EcoRI and SalI, blunting the ends using the KlenowThe mechanism by which Myc represses Tsp-1 transcription
fragment of DNA polymerase (Roche, Indianapolis, Indiana), and ligating itremains unclear. Previous reports have demonstrated that Myc
into pBabeZeo digested with SnaB1; the antisense orientation was confirmedis capable of inhibiting transcription of a Tsp-1 promoter con-
by restriction digest. The constructs pMIG-DNRhoA and pMIG-RhoCV14
struct (Thomas-Tikhonenko et al., 1996). However, Myc has also were gifts from Richard O. Hynes (MIT Center for Cancer Research). The
been hypothesized to affect the stability of the Tsp-1 transcript construct pEXV-RhoAV14 was a gift from Alan Hall (MRC, London). The
(Ngo et al., 2000). Transcriptional repression by Myc has been V12H-Ras mutants (a gift of Dr. Julian Downward) (Stratagene) were sub-
cloned from pSG5 into the EcoRI site of the pWZL-Blast retroviral vector anddemonstrated for several genes including p21CIP and p15INK4B
directionality was confirmed by immunoblot analysis using a Ras-specific(Mitchell and El-Deiry, 1999; Staller et al., 2001). In most cases,
antibody (SantaCruz Biotechnologies, Santa Cruz, California).this repression has been demonstrated to occur via binding to
The generation of the human embryonic kidney cells HA1E, HA1EhR,an INR element (Li et al., 1994). However, a search of the geno-
HA1EpR and the human mammary epithelial cells HMLE, HMLEhR, HMLEpR
mic TSP-1 DNA sequence has not revealed a consensus INR was described previously (Elenbaas et al., 2001; Hahn et al., 1999). HA1EhRV
site in proximity to the transcriptional start site. and HA1EpRV were generated by retroviral transduction of the parental
As previously stated, the Rho pathway is the downstream cells with pBabeZeo-VEGF, whereas HMLEhRV and HMLEpRV were trans-
duced with pWZLBlast-VEGF. HA1EhRAT was generated by transducingsignaling cascade that is activated by PI3 kinase and is required
HA1EhR with pBabeZeo-AT. HA1ERasC40, G37, and S35 cell lines werefor the repression of Tsp-1 (Figure 7). The involvement of Rho
created by transducing the parental HA1E cells with pWZL-RasC40, pWZL-could also be significant in other aspects of tumor progression.
RasG37, and pWZL-RasS35. HA1EpR-RhoAN19 and HA1EhR-RhoCV14For instance, it has been demonstrated that overexpression of
were created by transducing the parental cell lines with pMIG-RhoAN19
RhoC increases both the metastatic potential and motility of and pMIG-RhoCV12. Retroviruses were produced as previously described
human B16F0 melanoma cells and A375P amelanotic cells (Elenbaas et al., 2001).
(Clark et al., 2000). Therefore, the ability of RhoC to increase
Tumor formation assaysthe metastatic potential of tumor cells could be accomplished
Tumorigenicity of the cell lines created above was assessed by injectingvia its ability to increase both the motility and migration of the
2  106 cells subcutaneously, either with or without Matrigel (Becton Dickin-cells at the primary site and also their angiogenicity at their
son, Palo Alto, California), into nude mice that had been irradiated with 4
metastatic destination via downregulation of Tsp-1. It is likely grays 24 hr prior to injection. The tumor diameter was measured using
that the functions that have been ascribed to RhoC will be calipers and the diameter converted to volume using the equation 4/3r3.
applicable as well to RhoA. The two proteins are 92% identical
ELISA assaysin their amino acid sequences and both have been shown to
The kidney cells were grown in MEM  10% IFS in either 0.1% oxygenbe able to stimulate ROCK (Leung et al., 1996; Ridley, 1997;
or 20% oxygen for 48 hr. The mammary cells were grown in a 1:1 ratio ofSahai and Marshall, 2002). Moreover, as demonstrated here,
DMEM and F12 media with 5% fetal calf serum and 10 g/ml insulin, 10RhoA and RhoC are both able to stimulate Myc phosphorylation
ng/ml hEGF, and 1 g/ml hydrocortisone (Sigma Chemicals, St. Louis, Mis-
and Tsp-1 repression. souri). The conditioned media were filtered through 0.45 m syringe filters,
The regulation of angiogenesis is an essential, rate-limiting and the levels of VEGF were measured using an ELISA kit from R&D that
was specific for either murine or human VEGF (Minneapolis, Minnesota).process in tumor formation. Much work has gone into the eluci-
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VEGF levels were normalized against total protein from the cells used in the was prepared via T7 in vitro transcription from linearized pTRIPLEscript-
cyclophylin (Ambion, Austin, Texas) incorporating [-32P] UTP (NEN, Boston,assay.
Massachusetts) using MaxiScript T7 kit (Ambion). The probe specific for
ODC was prepared via T7 in vitro transcription from linearized pDP18-ODCWestern blotting
incorporating [-32P] UTP using MaxiScript T7 kit (Ambion). RPAs were thenFor Western blot analysis, the human embryonic kidney-derived cells were
performed using the RPA III kit (Ambion). The protected fragments were rungrown in MEM containing 10% IFS and then switched to MEM containing
on a Criterion 5% TBE-Urea gel (BioRad, Hercules, California), dried on 30.1% inactivated fetal calf serum (IFS) for 12 hr. The mammary epithelial-
mm filter paper, and visualized by autoradiography.derived cells were grown in a 1:1 mixture of DMEM and F12  5% fetal calf
serum (FCS) with 10 g/ml insulin, 10 ng/ml hEGF, and 1 g/ml hydrocorti-
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supported by the Damon Runyon Cancer Research Foundation (DRG-1587).Y27632 for 8 hr. Human breast cancer cell lines MDA-MB-231, MDA-MB-
435, MCF-7 were grown in DMEM containing 10% IFS and were switched
to 0.1% IFS for 2 hr followed by treatment with 10 M LY294002, Y27632
or mock treatment for 8 hr. SkBr3 and BT549 were grown in RPMI containing
10% FCS and switched to 0.1% FCS for 2 hr followed by treatment with Received: November 13, 2002
10 M LY294002, Y27632 or mock treatment for 8 hr. Revised: February 6, 2003
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